Associated Papers
Diabetes with GLP-1R polymorphism (rs3765467) accompanied by myotonic dystrophy: A case of myotonic dystrophy with p.R131Q polymorphism at the glucagon-like peptide-1 receptor (rs3765467) resulting in marked effects of its agonist, dulaglutide.
Kato K et al.
The American Journal of the Medical Sciences, 2025
Genetic variability in sodium-glucose cotransporter 2 and glucagon-like peptide 1 receptor effect on glycemic and pressure control in type 2 diabetes patients treated with SGLT2 inhibitors and GLP-1RA in the everyday clinical practice.
Tonin G et al.
Frontiers in Endocrinology, 2025
Association between polymorphisms of glucagon-like peptide-1 receptor gene and susceptibility to osteoporosis in Chinese postmenopausal women.
Bao X et al.
Journal of Orthopaedic Surgery and Research, 2024
Population-specific putative causal variants shape quantitative traits.
Koyama S et al.
Nature Genetics, 2024
Genetic studies of type 2 diabetes, and microvascular complications of diabetes.
Imamura M et al.
Diabetology International, 2024
Perspectives on genetic studies of type 2 diabetes from the genome-wide association studies era to precision medicine.
Imamura M et al.
Journal of Diabetes Investigation, 2024
GLP1R (glucagon-like-peptide-1 incretin receptor), diabetes and obesity phenotypes: An in silico approach revealed new pathogenic variants.
Knihs VM et al.
Diabetes & Metabolic Syndrome, 2024
Rare Heterozygous Loss-of-Function Variants in the Human GLP-1 Receptor Are Not Associated With Cardiometabolic Phenotypes.
Melchiorsen JU et al.
The Journal of Clinical Endocrinology and Metabolism, 2023
Rare Variants of Obesity-Associated Genes in Young Adults with Abdominal Obesity.
Bairqdar A et al.
Journal of Personalized Medicine, 2023
GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification.
Lagou V et al.
Nature Genetics, 2023
A whole-genome reference panel of 14,393 individuals for East Asian populations accelerates discovery of rare functional variants.
Choi J et al.
Science Advances, 2023
Association of GLP1R Polymorphisms With the Incretin Response.
Dorsey-Trevino EG et al.
The Journal of Clinical Endocrinology and Metabolism, 2022
Structural basis of ethnic-specific variants of PAX4 associated with type 2 diabetes.
Hosoe J et al.
Human Genome Variation, 2021
Pharmacogenetics of novel glucose-lowering drugs.
Rathmann W et al.
Diabetologia, 2021
Progress in Defining the Genetic Contribution to Type 2 Diabetes in Individuals of East Asian Ancestry.
Spracklen CN et al.
Current Diabetes Reports, 2021
Nutrient consumption-dependent association of a glucagon-like peptide-1 receptor gene polymorphism with insulin secretion.
Nishiya Y et al.
Scientific Reports, 2020
Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population.
Suzuki K et al.
Nature Genetics, 2019
Nonsynonymous Variants in PAX4 and GLP1R Are Associated With Type 2 Diabetes in an East Asian Population.
Kwak SH et al.
Diabetes, 2018
A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.
Han E et al.
Medicine, 2016
Association of genetic variants of the incretin-related genes with quantitative traits and occurrence of type 2 diabetes in Japanese.
Enya M et al.
Molecular Genetics and Metabolism Reports, 2014
Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery.
Koole C et al.
Molecular Endocrinology (baltimore, Md.), 2013
Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.
Mannino GC et al.
Molecular Diagnosis & Therapy, 2012
Pharmacological characterization of human incretin receptor missense variants.
Fortin JP et al.
The Journal of Pharmacology and Experimental Therapeutics, 2010
Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population.
Tokuyama Y et al.
Diabetes Research and Clinical Practice, 2004